Plus, news about Repare Therapeutics, DCx Biotherapeutics, Bloomsbury Genetic Therapies and Zucara Therapeutics:
Arvinas drops planned late-stage trials: The protein degrader specialist, along with its partner Pfizer, canceled plans for a ...
↧